Literature DB >> 15154933

Schizophrenia, the metabolic syndrome and diabetes.

R I G Holt1, R C Peveler, C D Byrne.   

Abstract

The prevalence of diabetes is increased in patients with schizophrenia. Although many reasons, including hereditary and lifestyle factors, contribute to this association, recently there has been heightened interest in the subject because of the link between the use of the newer atypical anti-psychotic drugs and the development of diabetes. These drugs cause significant weight gain and this may be one of the mechanisms by which they increase incident diabetes. The increased prevalence of diabetes among people with schizophrenia has implications for the delivery of care by psychiatrists, diabetologists and primary care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154933     DOI: 10.1111/j.1464-5491.2004.01199.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  21 in total

Review 1.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

2.  A parametric analysis of olanzapine-induced weight gain in female rats.

Authors:  G D Cooper; L C Pickavance; J P H Wilding; J C G Halford; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

3.  Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.

Authors:  Fernando Chacón; Fernando Mora; Alicia Gervás-Ríos; Inmaculada Gilaberte
Journal:  Ann Gen Psychiatry       Date:  2011-09-19       Impact factor: 3.455

4.  Gene expression profiling in rodent models for schizophrenia.

Authors:  Jessica E Van Schijndel; Gerard J M Martens
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

5.  The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets.

Authors:  N Sasaki; M Iwase; Y Uchizono; U Nakamura; H Imoto; S Abe; M Iida
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

6.  Metabolic syndrome in people with schizophrenia: a review.

Authors:  Marc DE Hert; Vincent Schreurs; Davy Vancampfort; Ruud VAN Winkel
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

Review 7.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

9.  Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.

Authors:  Kentaro Kawabe; Shinichiro Ochi; Yuta Yoshino; Yoko Mori; Hiroshi Onuma; Haruhiko Osawa; Yoshiki Hosoda; Shu-Ichi Ueno
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

Review 10.  Effect of atypical antipsychotics on fetal growth: is the placenta involved?

Authors:  Sandeep Raha; Valerie H Taylor; Alison C Holloway
Journal:  J Pregnancy       Date:  2012-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.